Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9LOK

The co-crystal structure of PTP1B complex with allosteric inhibitor Fumosorinone

This is a non-PDB format compatible entry.
Summary for 9LOK
Entry DOI10.2210/pdb9lok/pdb
DescriptorTyrosine-protein phosphatase non-receptor type 1, GLYCEROL, 5-(4-hydroxyphenyl)-1,4-bis(oxidanyl)-3-[(2~{E},4~{E},6~{Z},8~{E},10~{R},12~{R})-2,8,10,12-tetramethyltetradeca-2,4,6,8-tetraenoyl]pyridin-2-one, ... (4 entities in total)
Functional Keywordsphosphatase, co-crystal, allosteric inhibitor, ptp1b, hydrolase
Biological sourceHomo sapiens (human)
Total number of polymer chains2
Total formula weight71047.04
Authors
Zhang, J.,Lin, L.,Yuchi, Z.,Luo, D. (deposition date: 2025-01-23, release date: 2026-06-10)
Primary citationZhang, J.,Lin, L.,Gong, N.,Li, W.,Liu, Y.,Sundarraj, R.,Li, Y.,Dong, M.,Ma, J.,Woycechowsky, K.,Mei, K.,Ge, Y.,Yuchi, Z.,Luo, D.
Structural basis of Fumosorinone-mediated allosteric inhibition of PTP1B for cancer immunotherapy.
Commun Biol, 9:-, 2026
Cited by
PubMed Abstract: Protein Tyrosine Phosphatase 1B (PTP1B) is a key immune regulator in cancer and an attractive immunotherapy target, yet progress is limited by the lack of selective inhibitors. Here, we identify Fumosorinone (FU), a natural product from Isaria fumosorosea, as a potent and selective allosteric inhibitor of PTP1B. In a murine colon tumor model, FU enhances anti-tumor immunity by reshaping the microenvironment, strengthening CD8⁺ T-cell responses, and promoting M1-like macrophage polarization. Enzymatic and biophysical analyses confirm its potency and direct engagement with PTP1B. A co-crystal structure defines a previously uncharacterized allosteric pocket that stabilizes the inactive state of the enzyme. This pocket is poorly conserved across the PTP family, consistent with minimal activity toward related phosphatases except TCPTP. Guided by this insight, virtual screening identifies additional inhibitors. These findings provide a structural basis for selective PTP1B targeting and support future immunotherapy development and rational drug discovery efforts.
PubMed: 42209755
DOI: 10.1038/s42003-026-10329-2
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.5 Å)
Structure validation

254917

PDB entries from 2026-06-10

PDB statisticsPDBj update infoContact PDBjnumon